Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.9 USD | +0.07% | -4.05% | +4.68% |
Business Summary
Number of employees: 1,400
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Eiry Roberts
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-01-07 |
Bill Wilson
COO | Chief Operating Officer | - | 96-08-31 |
Chief Tech/Sci/R&D Officer | 65 | 92-12-31 | |
Gary Lyons
BRD | Director/Board Member | 73 | 93-01-31 |
Todd Tushla
IRC | Investor Relations Contact | - | - |
Ingrid Delaet
LAW | General Counsel | - | 20-12-31 |
David Boyer
PRN | Corporate Officer/Principal | 44 | 19-09-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Christine Poon
BRD | Director/Board Member | 71 | 23-07-10 |
Chairman | 75 | 10-02-07 | |
Richard Pops
BRD | Director/Board Member | 62 | 98-03-31 |
Gary Lyons
BRD | Director/Board Member | 73 | 93-01-31 |
Leslie Norwalk
BRD | Director/Board Member | 58 | 98-03-31 |
Shalini Sharp
BRD | Director/Board Member | 49 | 20-02-02 |
Johanna Mercier
BRD | Director/Board Member | 54 | 21-04-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 99,507,490 | 98,242,803 ( 98.73 %) | 0 | 98.73 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
VOYAGER THERAPEUTICS, INC. 18.58% | 8,575,316 | 18.58% | 71,346,629 $ |
Company contact information
Neurocrine Biosciences, Inc.
12780 El Camino Real
92130, San Diego
+858 617 7600
http://www.neurocrine.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.68% | 13.72B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+34.25% | 12.15B | |
-6.78% | 10.2B |
- Stock
- Equities
- Stock Neurocrine Biosciences, Inc. - Nasdaq
- Company Neurocrine Biosciences, Inc.